Business Context and Reporting Period
cbdMD, Inc. (YCBD), an emerging growth company incorporated in North Carolina, filed this Form 8-K on December 8, 2020. The filing reports the entry into a material definitive agreement for a firm commitment underwritten public offering of preferred stock.
Key Financial Metrics and Transaction Details
- Security Issued: 2,000,000 shares of 8.0% Series A Cumulative Convertible Preferred Stock.
- Offering Price: $7.50 per share.
- Gross Proceeds: $15.0 million (2,000,000 shares x $7.50).
- Net Proceeds: Approximately $13.7 million (before exercise of over-allotment option).
- Underwriting Discount: 7.25% of gross cash proceeds.
- Estimated Expenses: Approximately $215,000 (excluding underwriting discounts).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 300,000 additional shares.
- Warrant Issuance: A warrant to purchase 150,502 shares of common stock issued to the representative, exercisable at $3.74 per share.
- Use of Proceeds: General working capital.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with ThinkEquity, a division of Fordham Financial Management, Inc. The transaction is expected to close on December 11, 2020. The Company and certain executive officers have entered into Lock-Up Agreements restricting the sale of their securities for 60 days from the closing date.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected net proceeds, which are subject to risks and uncertainties detailed in the Company's other SEC filings. The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions. The filing explicitly states that the Underwriting Agreement is not intended to provide factual information about the Company beyond the terms of the agreement itself.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 11, 2020) and whether the over-allotment option was exercised.
- Review the Final Prospectus Supplement (dated December 8, 2020) for complete terms of the Series A Convertible Preferred Stock.
- Confirm the actual net proceeds received after deducting all underwriting discounts and expenses.
- Monitor the Company's use of proceeds to ensure alignment with the stated purpose of general working capital.
- Check for any subsequent filings regarding the exercise of the warrant issued to the underwriters.